^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Acrivon Therap

    i
    Other names: Acrivon
    Related tests:
    Evidence
    News
    13d
    ACR-368-201: A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma (clinicaltrials.gov)
    P2 | N=401 | Recruiting | Sponsor: Acrivon Therapeutics | Trial completion date: Apr 2027 ➔ Nov 2027 | Trial primary completion date: Oct 2026 ➔ May 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    gemcitabine • prexasertib (ACR-368)
    3ms
    Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory (Acrivon Press Release)
    ''Acrivon Therapeutics, Inc...discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA) certified laboratory, located on premises in Watertown.''
    Clinical